Cargando…
Management of patients with multiple myeloma during the COVID-19 pandemic
Autores principales: | Malard, Florent, Mohty, Mohamad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185930/ https://www.ncbi.nlm.nih.gov/pubmed/32353254 http://dx.doi.org/10.1016/S2352-3026(20)30124-1 |
Ejemplares similares
-
Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
por: Mohty, Mohamad, et al.
Publicado: (2020) -
Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019) -
Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies
por: El-Cheikh, Jean, et al.
Publicado: (2023) -
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022) -
Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma
por: Stocker, Nicolas, et al.
Publicado: (2020)